---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-121819"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:54:13.545011+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet enters global exclusive license with TAPI for innovative resmetirom API for FDC program

## Summary
- License grants Sagimet exclusive global rights to TAPI's innovative forms of resmetirom API for fixed-dose combination with denifanstat.
- Sagimet paid $2.5M upfront; TAPI may receive low single-digit royalties and up to $5.5M in manufacturing milestones.
- Phase 1 PK trial of denifanstat + resmetirom underway; topline data expected by end of 2025.
- Sagimet plans to select one TAPI resmetirom form for a single FDC tablet for Phase 3 study in H2 2026.
- Combination targets MASH cirrhosis (F4) where no approved therapies exist.

## SEC filing metadata
- accession: 0001104659-25-121819
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/0001104659-25-121819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-121819
- JSON: https://secwatch.observer/filing/0001104659-25-121819.json
- Plain text: https://secwatch.observer/filing/0001104659-25-121819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.